Objective: To investigate the relationship between early second trimester serum lipidomic variation and maternal glycemic traits at 28 weeks, and to identify predictive lipid biomarkers for Gestational Diabetes (GDM).
Introduction
Gestational diabetes (GDM) affects 9-26% of pregnancies (1) . It is clinically important because it increases the risk of obstetric complications (e.g. pre-eclampsia and shoulder dystocia), as well as neonatal complications (e.g. hypoglycemia and hyperbilirubinemia). In the multi-center Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study, a continuous linear relationship was shown between maternal glucose levels at 24-32 weeks of gestation and the odds of several adverse pregnancy outcomes, even for glucose levels well within the normal range (2) . This has provided impetus for the International Association of Diabetes and Pregnancy Study Groups (IADPSG) to recommend universal screening for GDM via the 75g
Oral Glucose Tolerance Test (OGTT) between 24-28 weeks gestation (3).
This recommendation by the IADPSG has not been uniformly adopted due to various concerns, including the implications on service provision, and the large number of normoglycemic women who will have undergo what can be an unpleasant and poorly tolerated test (4) . Some countries, such as the United Kingdom (4) and Italy (5), perform risk factor-based screening, with only high-risk individuals receiving the diagnostic 75g oral glucose tolerance tests. Specified risk factors include obesity, previous macrosomic baby, previous gestational diabetes, family history of diabetes and minority ethnic family origin with high prevalence of diabetes. In the United States, the American Diabetes Association and American College of Obstetricians and Gynecologists continue to endorse a two-step approach with an initial universal non-fasted 50g Glucose Load Test at 24-28 weeks gestation (6) .
Another recognized limitation of screening for GDM at 24-28 weeks gestation is the delay in detecting cases of GDM that developed in the first or early second trimesters. By the time of screening, significant increased fetal adiposity may have developed (4, 7, 8) . Although performed in a high-risk ethnic minority population, Agarwal and colleagues showed that over 40% of GDM cases could be diagnosed by a 75g OGTT performed before 18 weeks gestation (9) . These limitations of universal 24-28 week OGTT support the potential value of predictive early gestational biomarkers for GDM. Biomarkers that have been studied include fasting plasma glucose (9) and more recently maternal metabolites (10, 11) , plasma proteins (12) and miRNA (13) using high throughput technologies. Although these efforts
have not yet informed clinical strategies, the results of metabolomic studies in particular have shed valuable insights on the pathophysiology of GDM (11, 14) .
Variations in lipid profiles have yet to be comprehensively studied, even though changes in maternal lipid metabolism are well-described from the beginning of pregnancy (15) . In early pregnancy, plasma lipids, including triglycerides, phospholipids and cholesterol decrease, before steadily increasing from week 8 onwards (15) . The rise in triglycerides is accompanied by an increase in VLDL, LDL and HDL levels (16) . Changes in lipids during GDM have also been observed, with GDM women having higher serum triglyceride levels, but lower LDL levels, compared to normoglycemic pregnant women (17) .
Therefore, we hypothesized that lipidomic variation in early second trimester maternal serum samples could be associated with later glucose tolerance measured at 28 weeks. Confirmation of this hypothesis would enable identification of candidate lipid biomarkers that are predictive of GDM, so as to improve GDM screening and provide mechanistic insights into the pathophysiology of GDM.
Research Design and Methods

Recruitment and sample collection
The Cambridge Baby Growth Study (CBGS) is a prospective longitudinal study that has been described previously (18) (19) (20) . Briefly, 2212 women in early pregnancy were recruited between 2001 and 2009 from ultrasound clinics at the Rosie Maternal Hospital, Cambridge, UK. Such dating scans are routinely offered to all pregnant women receiving antenatal care, and are performed at 8-14 weeks gestation.
Shortly after recruitment, at 15.2 ± 0.07 weeks gestation, a non-fasting venous blood sample was collected if women consented. After clotting and within 2 hours of sample collection, these samples were centrifuged at 3,000G for 10 min and the serum separated and stored at -80 o C. They were maintained at -80 °C until analysis, with the exception of a single freeze-thaw cycle to prepare the necessary aliquots for lipid analysis. A total of 1260 serum samples were collected.
All participants were also invited for a standard 75g OGTT, which was performed at 28 weeks gestation after an overnight fast. A total of 1069 women underwent the OGTT. Plasma glucose levels were analyzed by the standard glucose oxidase method.
Cohort selection
For this study, we excluded OGTT participants who (i) were missing either fasting or 1-hour (1h) post-load venous plasma glucose level measurements (n=10), (ii) subsequently gave birth to twins (n=17), or (iii) did not provide a early second trimester serum sample (n=219 women. Women in the discovery cohort were selected because they had data on other genetic or phenotypic traits, which other ongoing studies in our group were interested in correlating lipidomic variation with.
There were two differences in clinical characteristics between the discovery and validation cohorts. First, 1h post-load glucose levels were 0.27mM higher in the validation cohort (Table 1 ). This result was of borderline significance on univariate testing (p=0.05), and non-significant when multiple testing was accounted for using the Benjamini-Hochberg method (p=0.175). Importantly, there was no significant difference in the proportion of cases with GDM in the two groups. Second, samples were taken in the validation cohort at a slightly later gestation, approximately 0.5 weeks later.
Ethical approval
The study protocol was approved by the local research ethics committee, Addenbrooke's Hospital, Cambridge, UK. Written informed consent was obtained from all participants.
Lipid biomarker analyses
In the discovery cohort the lipids were profiled by direct infusion mass spectrometry as described previously (21, 22) . For biomarker validation, we used a Liquid
Chromatography-Mass Spectrometry (LC-MS) method as described before (23) . Standard linear and logistic regression techniques were used to assess the association between candidate lipid biomarkers and maternal OGTT results or GDM status. GDM was defined based on fasting and 1h post-load glucose levels using IADPSG thresholds, i.e. ≥5.1 and 10.0mM respectively. 2h post-load data was unavailable for most women and was omitted from our case definition for uniformity. This is acceptable as only 7% of UK women with GDM are diagnosed based on the 2h measurement alone (1).
Statistical analysis
Logistic regression was used to combine the predictive ability of candidate lipid biomarkers, which was then assessed using Receiver Operating Characteristics (ROC) plots. Where backward stepwise selection was used, a significance threshold of 0.10 for removal was employed. Linear discriminant analysis was used to ensure the robustness of these results.
The threshold for statistical significance was 0.05. For the discovery cohort uncorrected p-values were considered, whereas in the validation cohort p-values were corrected for multiple testing using the Benjamini-Hochberg method. Values in the text are given as mean ± SE unless otherwise specified. Regression coefficients were standardized by the predictor, i.e. change in response variable for each standard deviation increase in the predictor.
PLS and PLS-DA regression was performed using SIMCA version 14 (MKS Umetrics AB, Umeå, Sweden). All other analyses were performed using SPSS version 21
(IBM, Armonk, NY, USA).
Results
Association between early second trimester lipidomic variation and 28-week glucose tolerance
Analysis of the discovery cohort was confined to 196 samples as 4 samples were found to be unsuitable for analysis due to hemolysis. In these samples, 189 lipid species were detected.
A PLS model was constructed to examine the extent to which early second trimester lipidomic variation explained post-load venous glucose levels during a OGTT at 28
weeks. The resulting model yielded 1 fitted component, which used 15% of lipidomic variation (R 2 X) to explain 11% (R 2 Y) of variation in post-load glucose levels. This was robust to internal cross-validation, yielding a Q 2 of 4%.
Because some lipid species may show non-linear relationships with post-load glucose levels, we divided participants into tertiles of OGTT levels, and constructed a PLS-DA model to explain membership in the top tertile. The resulting model also yielded a single component, which used 15% of lipidomic variation to explain 9% of the variation in top tertile membership, with a Q 2 of 1.31%.
Similar PLS and PLS-DA models were also constructed to explore the relationship between lipidomic variation and fasting plasma glucose levels. However, the models were overfitted, with the PLS and PLS-DA models yielding a Q 2 of -3% (R 2 X=15%, R 2 Y=9%) and -10% (R 2 X=9%, R 2 Y=8%) respectively. These models were not used in subsequent analyses.
Identification of lipid biomarkers of post-load plasma glucose levels
From each of the two models considering post-load glucose levels, approximately 10 lipids with the highest VIP scores were selected, with the exact cut-point selected using a graphical method (Fig. 1a, b ). The PLS model yielded 9 lipid species and the PLS-DA model 10 species, with 5 lipid species being identified in both models. One of the species annotated as DG-H2O(32:0) was likely to be an in-source fragment of a different lipid species. As in-source fragments are artifacts of mass spectrometry, this species was disregarded, leaving a total of 13 lipid species identified.
The 13 lipid species were regressed against post-load glucose levels or membership in the top tertile thereof. To ensure that they were not simply surrogates for known risk factors of GDM, maternal age and pre-pregnancy BMI were adjusted for. This resulted in 10 of the 13 lipid species having a nominally significant association with post-load glucose levels and/or the top tertile thereof (Supplementary Table S1 ). The Table S2 ).
Further examination of the correlations between these 10 lipid species revealed clustering into 2 large groups (Fig. 1c) . The first group contained the choline ether phospholipids, whereas the second group contained triglycerides and a phosphatidylcholines.
Validation of lipid biomarkers of post-load plasma glucose levels
These 10 candidate lipid biomarkers were measured in the validation set of 617 subjects using a LC-MS method. This provided additional chromatographic information, eliminating any possible artifacts introduced by the shotgun approach in the discovery set. With this method we were unable to detect PCae(44:4) in our samples, suggesting that this putative signal in the discovery set was an artifact, and it was omitted from further analysis. We also omitted 20 samples in which none of the remaining 9 lipid species were detectable, as this was likely indicative of poor sample quality. This left data on the 9 candidate lipid biomarkers in 597 subjects for analysis.
Of the 9 remaining lipid species, 5 showed significant associations with post-load glucose levels even after adjustment for maternal age and BMI and correction for multiple testing (Table 2) . TG(51:1), TG(48:1) and PC(32:1) were positively associated with maternal post-load glucose levels, whereas PCae(40:3) and PCae(40:4) were inversely associated with maternal post-load glucose levels.
Logistic regression against membership in the top tertile of post-load glucose levels did not validate any additional candidate lipid species, nor did adjusting for gestational age at the time of serum sample collection (data not shown).
As fasting and post-load glucose levels have common pathophysiological determinants and were moderately correlated in our cohort (r=0.343, p<0.001), we tested the 9 putative lipid biomarkers for an association with fasting glucose levels (data not shown). TG(51:1) and PCae(40:4) showed significant associations with fasting glucose levels, even after adjusting for multiple testing. However, after adjusting for maternal age and BMI, only TG(51:1) remained significant (0.06mM per SD increase, p-value=0.003, Benjamini-Hochberg p-value=0.02).
Lipid predictors of Gestational Diabetes
Of the 597 subjects in the validation cohort, 53 met the criteria for GDM. To assess the combined predictive ability of these 4 lipid species, logistic regression was used to calculate the probability of GDM status of each subject, and the probability scores used to construct a ROC curve (Fig. 2b) . This yielded an AUC of 0.709 ± 0.040 (p=4.85E-7). Similar results were obtained using linear discriminant analysis.
Of the 597 subjects, 410 (including 37 GDM cases) had available data on maternal age and BMI. This enabled us to assess the additional predictive power conferred by these 4 lipid biomarkers over maternal age and BMI alone. In this sub-group, maternal age and BMI produced an AUC of 0.689 ± 0.046 (p=1.54E-4), and further inclusion of the 4 lipid biomarkers increased the AUC to 0.741 ± 0.045 (p=1.33E-6) (Fig. 2c) . Graphically, the improvement in AUC was most marked at stringent thresholds, i.e. enhancing the sensitivity at high levels of specificity. For instance at 91.7% specificity, sensitivity is 21.6% based on traditional risk factors, but raised to 48.6% when lipid predictors are included. In addition, there was some improvement at high levels of sensitivity, for instance at 97.3% sensitivity, where the inclusion of lipid predictors raised specificity from 9.9% based on traditional risk factors alone to 24.9%.
Finally, we sought to identify the most parsimonious model from these 6 potential predictive variables. Using a backward stepwise selection algorithm, the only terms left in the model were Maternal BMI, TG(48:1) and PCae(40:4). This yielded an AUC of 0.732 ± 0.045 (p=3.28E-6), which is similar to the model including all 6 predictors.
Conclusions
In this unselected cohort of predominantly Caucasian pregnant women, using an unbiased lipidomics approach and a pre-assigned validation cohort, we show for the first time that specific lipid species in the maternal early second trimester lipid profile are associated with maternal glycemic traits assessed by standard 75g oral glucose tolerance testing at 28 weeks. We identified 4 lipid biomarkers, i.e. TG(51:1), TG(48:1), PC(32:1) and PCae(40:4), that predict later GDM independent of maternal age and BMI, and could potentially enhance the performance of existing risk-factor based screening approaches used in many countries.
The performance of clinical risk-factor based screening has been examined in many different populations. A recent study in an Australian population compared the performance of the NICE, ADA and Australasian Diabetes in Pregnancy Society riskfactor based screening guidelines, yielding sensitivities of 92%, 100% and 99%, and specificities of 32.4%, 3.9% and 13.7% respectively (24) . This and other studies reveal limited test performance, with the need for low levels of specificity to achieve the high levels of sensitivity.
The 4 lipid biomarkers that we identified have moderate predictive performance, with an estimated AUC of 0.709. This is comparable to other early pregnancy biomarkers, including conventional biomarkers fasting plasma glucose (estimated AUC=0.579) (9), HbA 1C (AUC in high risk population=0.67) (25) , triglycerides (AUC=0.55-0.61) and triglycerides to HDL ratio (AUC=0.62) (26) , as well as novel biomarkers such as second trimester serum miRNA (AUC=0.669) (13) . Furthermore the lipid biomarkers that we derived were specifically identified to predict GDM independent of maternal age and BMI, and thus can enhance the predictive performance of existing risk factor-based approaches. Indeed, inclusion of the 4 lipid biomarkers to maternal age and BMI increased the AUC from 0.689 to 0.741.
The enhancement of sensitivity at high levels of specificity was particularly marked.
Although for the purpose of predicting GDM, our data on the clinical performance of lipid biomarkers must be considered very preliminary, lipid biomarkers may potentially have a role in identifying high-risk women who should receive an immediate/early second trimester OGTT.
The lipid biomarkers we identified can be divided into two groups. TG(51:1), TG (48:1) and PC (32:1) (27) , and PC(32:1) levels are raised in AusDiab subjects with Type 2 Diabetes (28). These 3 lipid species are notable for the presence of a single double bond, which implies the presence of a monounsaturated fatty acid (MUFA), predominantly palmitoleate and to a lesser extent, oleate, on closer inspection of LC-MS spectra in our analysis. In one study, palmitoleate content within circulating phospholipids was found to be associated with increased insulin resistance (29) . As circulating palmitoleate is principally synthesized in the liver in humans, this may reflect hepatic insulin resistance, in line with our finding that TG(51:1) is associated with fasting plasma glucose levels (30 with results of an untargeted metabolomic screen using fasted serum samples from women at 28 weeks gestation who were enrolled in the HAPO study (35) , in which heptadecanoic acid was raised in subjects with fasting plasma glucose levels in the 90 th percentile but with similar BMI to controls. This may be due to genuine differences in the pathophysiology of GDM and Type 2 Diabetes, but may also reflect the fact that the studies of Type 2 Diabetes measured the fatty acid content in phospholipids, whereas the latter study of pregnant women measured free fatty acids (35) . This underscores the advantage of intact lipid studies as opposed to fattyacid profiling (30) , which is a strength of our study.
The other group of lipid biomarkers identified, i.e. the choline ether phospholipids PCae(40:3) and PCae(40:4), were inversely associated with maternal glucose levels. This is consistent with an earlier report from the AusDiab cohort in which ether phospholipids were inversely related with post-load glucose levels and reduced in patients with diabetes (28) . The physiological function of ether phospholipids remains largely unknown (36), but they have been implicated as physiological ligands of PPARγ (37) . Intriguingly, SCD1 is a target of PPARγ, potentially providing a mechanistic link between low ether phospholipids, and high levels of palmitoleateand oleate-containing lipids (32) .
The broad overlap between our lipid biomarkers and those identified in studies of Type 2 Diabetes may be due to the fact that lipid profiles were derived from samples obtained early in pregnancy, reflecting the contribution of pre-existing insulin resistance to the development of Gestational Diabetes. Indeed, it will be ideal to obtain a pre-conceptional sample as well as one during pregnancy, to identify lipid biomarkers which reflect the pathophysiological contribution of pregnancy itself.
Nevertheless, this explanation of our findings is made less likely by the fact that GWAS studies have revealed a broadly shared genetic architecture between GDM and Type 2 Diabetes, and metabolomic studies from later in pregnancy, including one using samples from 28 weeks gestation, have shown overlapping metabolic signatures between GDM and Type 2 diabetes (11, 14, 35) .
There are several limitations to our study. First, while we validated our candidate lipid biomarkers using a pre-defined subset, these biomarkers have not been externally validated, for example in populations of high-risk ethnicities. Second, our study was not designed to demonstrate the superiority of a lipid biomarker and riskfactor based approach compared to a risk-factor based screening alone. additional variability might be small compared to existing inter-and intra-subject variation (38) . Our re-analysis of data from Begum and colleagues (38) suggests that variance is partitioned between inter-subject differences, intra-subject differences not due to meal time, and the effect of meal time in the proportion 62%, 31% and 7%, albeit the population that they studied was less heterogeneous than the CBGS. There were no potential conflicts of interests reported. This work has not been published elsewhere, either in whole or in part. 
